Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 02:22 PM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 02:17 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing improved recurrence-free survival when combined with Keytruda, leading to a 177% stock surge. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 02:12 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing improved recurrence-free survival when combined with Keytruda, leading to a 177% stock surge. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 02:07 PM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer treatment, with Moderna shares surging 177%, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 02:02 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a material positive catalyst that led to a 177% stock surge. This supports a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 01:57 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing improved recurrence-free survival when combined with Keytruda, and the stock surged 177% on the news. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 01:52 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer treatment, leading to a 177% stock surge, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 01:47 PM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer treatment, showing longer recurrence-free survival compared to Keytruda alone. Moderna shares surged 177%, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 01:42 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 01:37 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a material positive catalyst that drove a 177% share increase. This supports a BUY operation.